![\"Lonza](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/97fe53d38de6b62ec95e4a2330c379bb077d24e1-91121181.jpg\")
<\/p>\n <\/p>\n
Around 40 relocations have been confirmed to the Keystone-ATS news agency by both the Unia trade union and canton Valais. <\/p>\n
Keystone-SDA <\/p>\n
The Swiss biopharmaceutical contract manufacturer Lonza plans to relocate around 40 jobs, including some from Visp in canton Valais, to the Indian city of Hyderabad by the end of 2026.\n<\/p>\n
Listen to the article <\/p>\n
Listening the article <\/p>\n
Toggle language selector <\/p>\n
English (US) <\/p>\n
English (British) <\/p>\n
Generated with artificial intelligence. <\/p>\n
This content was published on <\/p>\n
March 18, 2026 – 16:21\n<\/p>\n
+Get the most important news from Switzerland in your inbox<\/a><\/p>\n \u201cLonza is extending its centralised services model, which currently covers finance, human resources, IT and purchasing, to take on additional functions such as quality (control), supply chain and marketing,\u201d said the Lonza press office, contacted by the Keystone-ATS news agency on Wednesday.<\/p>\n \n More<\/p>\n More <\/p>\n Pharma supply chains\n <\/p>\n Lonza sells off its capsules division to British firm <\/p>\n This content was published on <\/p>\n Mar 7, 2026 <\/p>\n The Swiss firm is selling its capsules and health ingredients business to Lone Star Funds for CHF2.3 billion ($3 billion). <\/p>\n <\/p>\n Read more: Lonza sells off its capsules division to British firm \u201cThe employees affected by this restructuring do not benefit from a collective labour agreement but from individual contracts,\u201d Barbara Lanthemann, the industry union secretary at Unia Valais, told Keystone-ATS.<\/p>\n Precise figures not disclosed<\/p>\n \u201cCertain activities and functions will be progressively transferred to our low-cost centres, including some functional positions currently based in Visp,\u201d the multinational said, declining to cite numbers.<\/p>\n The figure of around 40 relocations was confirmed to Keystone-ATS by both the Unia trade union and canton Valais, although the number of employees at the Visp site was not disclosed by the company.<\/p>\n \u201cThe creation of a new centre of excellence in Hyderabad\u201d, after those in Manchester and San Jos\u00e9 (Costa Rica), \u201cwill increase productivity, strengthen our working methods globally and expand access to India\u2019s vast talent pool. This strategic initiative will create scalable and sustainable capabilities, while enabling our core functions to support the short- and long-term financial and growth objectives of our global business,\u201d Lonza said.<\/p>\n Welcome to Hyderabad<\/p>\n The choice to set up in India is no accident. Hyderabad is considered a global hub for IT and technology. The city of over ten million inhabitants is considered a major site for software development, artificial intelligence (AI), the pharmaceutical industry and biotechnology. Tech giants such as Microsoft, Google and Amazon have made very significant investments there in recent years.<\/p>\n Employees who do not wish to leave canton Valais for India should be offered the possibility of continuing their professional activities in Visp. \u201cLonza is committed, as far as possible, to finding internal solutions for the employees concerned in Visp and at other sites,\u201d the company said.<\/p>\n \u201cThis initiative (Project Orbit) aims to ensure the scalable and sustainable functional support necessary for continued growth of our workforce at our main sites and markets, particularly in the areas of production, manufacturing and associated operational and commercial functions,\u201d Lonza added.<\/p>\n The Basel-based firm has around 4,500 employees in Visp, of whom approximately 1,500 work in production. \u201cThis sector is not affected by this relocation,\u201d Lanthemann said.<\/p>\n \n More<\/p>\n More <\/p>\n Moderna stands by partnership with Lonza <\/p>\n This content was published on <\/p>\n Sep 25, 2023 <\/p>\n Despite production of mRNA for the Covid-19 vaccine ending at the Lonza site in Visp, Moderna is maintaining its strategic partnership with the Valais company, assures the boss of the American group. <\/p>\n![\"Lonza](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/cd58a357fb016f74b2f069e9e4792794acc0842d-91053537.jpg\")
<\/p>\n
\n <\/a><\/p>\n![\"Lonza\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/a7a7a5994c2cb85609232e991558c588-lonza-data.jpg\")
<\/p>\n